Orthocell poised for revenue uplift following FDA clearance for...
Orthocell Ltd finished the March 2025 quarter with major progress towards commercialising its regenerative medicine portfolio, headlined by the post-quarter US Food and Drug Administration (FDA) clearance for its flagship Remplir™ nerve repair device. …